secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2024-04-24T23:59:59+00:00
Accession:  0001048477-24-000066
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q1 revenue $649M (+9% YoY); raises non-GAAP EPS and margin guidance
----------------------------------------------------------------------------

- GAAP diluted EPS $0.46 (+70% YoY); Non-GAAP diluted EPS $0.71 (+18% YoY).
- VOXZOGO revenue $153M (+74% YoY); over 3,100 children treated (+102% YoY).
- Full-year 2024 total revenue reaffirmed; non-GAAP margin and EPS guidance raised on $35-40M net OpEx savings.
- R&D portfolio prioritized: accelerated BMN 333, BMN 349, BMN 351; discontinued BMN 331, 255, 355, 365.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847724000066/0001048477-24-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847724000066/bmrn-20240424.htm
  HTML page:      https://secwatch.observer/filing/0001048477-24-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer